These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20481262)

  • 1. Where are we going with drugs to treat MS? Will cost continue to increase?
    Oger J; AlKhawajah M
    Can J Neurol Sci; 2010 May; 37(3):305-8. PubMed ID: 20481262
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing use of disease modifying drugs for MS in Canada.
    Rotstein DL; Mamdani M; O'Connor PW
    Can J Neurol Sci; 2010 May; 37(3):383-8. PubMed ID: 20481274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relevance of multiple sclerosis drugs in private health insurance (PHI)].
    Wild F
    Versicherungsmedizin; 2015 Jun; 67(2):78-81. PubMed ID: 26281288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data watch. How employers are tackling Rx costs.
    Bus Health; 1999 Jul; 17(7):48. PubMed ID: 10539172
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription drugs: recent trends in utilization, expenditures, and coverage.
    Sethi RC
    EBRI Issue Brief; 2004 Jan; (265):1-35. PubMed ID: 14969223
    [No Abstract]   [Full Text] [Related]  

  • 6. Statistics and drug utilization: are prescribing rates really that high?
    Morgan S
    CMAJ; 2001 Nov; 165(11):1507-8. PubMed ID: 11762577
    [No Abstract]   [Full Text] [Related]  

  • 7. Expenditures for prescription drugs: too much or not enough?
    Schumock GT; Walton SM
    Healthc Financ Manage; 2003 Oct; 57(10):34-8, 41. PubMed ID: 14560578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increasing drug costs. The society's drug expenditures are strongly increasing. If this trend continues we have to make other priorities].
    Andreasen J
    Ugeskr Laeger; 2003 Jul; 165(29):2873-6. PubMed ID: 12908355
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in costs of antipsychotics in France.
    Verdoux H; Tournier M
    Eur Psychiatry; 2009 May; 24(4):214-5. PubMed ID: 19195851
    [No Abstract]   [Full Text] [Related]  

  • 10. Defying the prescription. Forget forecasts--drug sales soar under managed care.
    Hensley S
    Mod Healthc; 1998 Apr; 28(15):42. PubMed ID: 10178321
    [No Abstract]   [Full Text] [Related]  

  • 11. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cholesterol-lowering medications in the United States from 1991 to 1997.
    Siegel D; Lopez J; Meier J
    Am J Med; 2000 Apr; 108(6):496-9. PubMed ID: 10781783
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug costs may top $750 PMPY by 2004.
    Capitation Rates Data; 2000 Oct; 5(10):115-8. PubMed ID: 11147537
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antiepileptic treatment nearly six times more expensive since 1990].
    Persson PM; Russom A; Tomson T
    Lakartidningen; 2003 Jan; 100(1-2):42-6. PubMed ID: 12572136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managed care outlook. What's behind increases in pharmaceutical spending?
    Manag Care; 1998 Feb; 7(2):70. PubMed ID: 10178891
    [No Abstract]   [Full Text] [Related]  

  • 16. Projecting future drug expenditures--1998.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1998 Jan; 55(2):127-36. PubMed ID: 9465976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonprescription medicine use in a multiple sclerosis clinic population.
    Tremlett HL; Wiles CM; Luscombe DK
    Br J Clin Pharmacol; 2000 Jul; 50(1):55-60. PubMed ID: 10886119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple sclerosis: cost of the illness].
    Tissot E; Woronoff-Lemsi MC
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1169-74. PubMed ID: 11787352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
    Fried I; Beam AL; Kohane IS; Palmer NP
    JAMA Intern Med; 2017 Nov; 177(11):1689-1690. PubMed ID: 28973537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stats & facts. The increasing dominance of the pharmacy benefits manager.
    Manag Care Interface; 1998 May; 11(5):46-7. PubMed ID: 10181551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.